Advanced search
Publication Cover
Pain Management Volume 4, 2014 - Issue 2
Submit an article Journal homepage
234
Views
0
CrossRef citations to date
0
Altmetric
Review

Botulinum Toxin for Neuropathic Pain and Spasticity: An Overview

E Alexandra Brown1 Department of Neurology, Mount Sinai Medical Center, Box 1052, New York, NY10029, USAView further author information
,
Sonja G Schütz1 Department of Neurology, Mount Sinai Medical Center, Box 1052, New York, NY10029, USAView further author information
&
David M Simpson1 Department of Neurology, Mount Sinai Medical Center, Box 1052, New York, NY10029, USACorrespondence[email protected]
View further author information
Pages 129-151 | Published online: 05 Mar 2014

References

  • Jabbari B , MachadoD. Treatment of refractory pain with botulinum toxins – an evidence-based review. Pain Med.12(11) , 1594–1606 (2011).
  • Grumelli C , VerderioC, PozziD, RossettoO, MontecuccoC, MatteoliM. Internalization and mechanism of action of clostridial toxins in neurons. Neurotoxicology26(5) , 761–767 (2005).
  • Welch MJ , PurkissJR, FosterKA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon38(2) , 245–258 (2000).
  • Durham PL , CadyR, CadyR. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache44(1) , 35–42; discussion 42–43 (2004).
  • Araque A , LiN, DoyleRT, HaydonPG. SNARE protein-dependent glutamate release from astrocytes. J. Neurosci.20(2) , 666–673 (2000).
  • Pavone F , LuvisettoS. Botulinum neurotoxin for pain management: insights from animal models. Toxins2(12) , 2890–2913 (2010).
  • Francisco GE , TanH, GreenM. Do botulinum toxins have a role in the management of neuropathic pain? A focused review. Am. J. Phys. Med. Rehabil.91(10) , 899–909 (2012).
  • Meng J , OvsepianSV, WangJ et al. Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential. J. Neurosci. 29(15) , 4981–4992 (2009).
  • Simpson DM , GraciesJM, GrahamHK et al. Assessment. Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 70(19) , 1691–1698 (2008).
  • Wissel J , WardAB, ErztgaardP et al. European consensus table on the use of botulinum toxin type A in adult spasticity. J. Rehabil. Med. 41(1) , 13–25 (2009).
  • Sheean G , LanninNA, Turner-StokesL, RawickiB, SnowBJ, Cerebral Palsy I. Botulinum toxin assessment, intervention and after-care for upper limb hypertonicity in adults: international consensus statement. Eur. J. Neurol.17(Suppl. 2) , 74–93 (2010).
  • Mohammadi B , BalouchSA, DenglerR, KolleweK. Long-term treatment of spasticity with botulinum toxin type A: an analysis of 1221 treatments in 137 patients. Neurol. Res.32(3) , 309–313 (2010).
  • Muller F , CugyE, DucerfC et al. Safety and self-reported efficacy of botulinum toxin for adult spasticity in current clinical practice: a prospective observational study. Clin. Rehab. 26(2) , 174–179 (2012).
  • French J , GronsethG. Lost in a jungle of evidence: we need a compass. Neurology71(20) , 1634–1638 (2008).
  • Argoff CE . A focused review on the use of botulinum toxins for neuropathic pain. Clin. J. Pain18(6 Suppl.) , S177–S181 (2002).
  • Liu HT , TsaiSK, KaoMC, HuJS. Botulinum toxin A relieved neuropathic pain in a case of post-herpetic neuralgia. Pain Med.7(1) , 89–91 (2006).
  • Sotiriou E , ApallaZ, PanagiotidouD, IoannidisD. Severe post-herpetic neuralgia successfully treated with botulinum toxin A: three case reports. Acta Derm. Venereol.89(2) , 214–215 (2009).
  • Klein AW . The therapeutic potential of botulinum toxin. Dermatol. Surg.30(3) , 452–455 (2004).
  • Xiao L , MackeyS, HuiH, XongD, ZhangQ, ZhangD. Subcutaneous injection of botulinum toxin a is beneficial in postherpetic neuralgia. Pain Med.11(12) , 1827–1833 (2010).
  • Apalla Z , SotiriouE, LallasA, LazaridouE, IoannidesD. Botulinum toxin A in postherpetic neuralgia: a parallel, randomized, double-blind, single-dose, placebo-controlled trial. Clin. J. Pain29(10) , 857–864 (2013).
  • Wu CJ , LianYJ, ZhengYK et al. Botulinum toxin type A for the treatment of trigeminal neuralgia. results from a randomized, double-blind, placebo-controlled trial. Cephalalgia 32(6) , 443–450 (2012).
  • Bohluli B , MotamediMH, BagheriSC et al. Use of botulinum toxin A for drug-refractory trigeminal neuralgia. preliminary report. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 111(1) , 47–50 (2011).
  • Turk U , IlhanS, AlpR, SurH. Botulinum toxin and intractable trigeminal neuralgia. Clin. Neuropharmacol.28(4) , 161–162 (2005).
  • Piovesan EJ , TeiveHG, KowacsPA, Della Coletta MV, Werneck LC, Silberstein SD. An open study of botulinum-A toxin treatment of trigeminal neuralgia. Neurology65(8) , 1306–1308 (2005).
  • Zuniga C , DiazS, PiedimonteF, MicheliF. Beneficial effects of botulinum toxin type A in trigeminal neuralgia. Arq. Neuropsiquiatr.66(3A) , 500–503 (2008).
  • Borodic GE , AcquadroMA. The use of botulinum toxin for the treatment of chronic facial pain. J. Pain3(1) , 21–27 (2002).
  • Volcy M , TepperSJ, RapoportAM, SheftellFD, BigalME. Botulinum toxin A for the treatment of greater occipital neuralgia and trigeminal neuralgia: a case report with pathophysiological considerations. Cephalalgia26(3) , 336–340 (2006).
  • Yoon SH , MerrillRL, ChoiJH, KimST. Use of botulinum toxin type A injection for neuropathic pain after trigeminal nerve injury. Pain Med.11(4) , 630–632 (2010).
  • Ngeow WC , NairR. Injection of botulinum toxin type A (BOTOX) into trigger zone of trigeminal neuralgia as a means to control pain. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.109(3) , e47–50 (2010).
  • Allam N , Brasil-NetoJP, BrownG, TomazC. Injections of botulinum toxin type a produce pain alleviation in intractable trigeminal neuralgia. Clin. J. Pain21(2) , 182–184 (2005).
  • Micheli F , ScorticatiMC, RainaG. Beneficial effects of botulinum toxin type a for patients with painful tic convulsif. Clinical Neuropharmacol.25(5) , 260–262 (2002).
  • Felicio AC , Godeiro Cde O Jr, Borges V, Silva SM, Ferraz HB. Bilateral hemifacial spasm and trigeminal neuralgia: a unique form of painful tic convulsif. Mov. Disord.22(2) , 285–286 (2007).
  • Ranoux D , AttalN, MorainF, BouhassiraD. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann. Neurol.64(3) , 274–283 (2008).
  • Wittekindt C , LiuWC, PreussSF, Guntinas-LichiusO. Botulinum toxin A for neuropathic pain after neck dissection: a dose-finding study. Laryngoscope116(7) , 1168–1171 (2006).
  • Breuer B , SperberK, WallensteinS et al. Clinically significant placebo analgesic response in a pilot trial of botulinum B in patients with hand pain and carpal tunnel syndrome. Pain Med. 7(1) , 16–24 (2006).
  • Tsai CP , LiuCY, LinKP, WangKC. Efficacy of botulinum toxin type a in the relief of Carpal tunnel syndrome: A preliminary experience. Clin. Drug Investig.26(9) , 511–515 (2006).
  • Yuan RY , SheuJJ, YuJM et al. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology 72(17) , 1473–1478 (2009).
  • Safarpour D , SalardiniA, RichardsonD, JabbariB. Botulinum toxin A for treatment of allodynia of complex regional pain syndrome: a pilot study. Pain Med.11(9) , 1411–1414 (2010).
  • Carroll I , ClarkJD, MackeyS. Sympathetic block with botulinum toxin to treat complex regional pain syndrome. Ann. Neurol.65(3) , 348–351 (2009).
  • Kharkar S , AmbadyP, VenkateshY, SchwartzmanRJ. Intramuscular botulinum toxin in complex regional pain syndrome: case series and literature review. Pain Physician14(5) , 419–424 (2011).
  • Birthi P , SloanP, SallesS. Subcutaneous botulinum toxin A for the treatment of refractory complex regional pain syndrome. PM R4(6) , 446–449 (2012).
  • Wu H , SultanaR, TaylorKB, SzaboA. A prospective randomized double-blinded pilot study to examine the effect of botulinum toxin type A injection versus lidocaine/depomedrol injection on residual and phantom limb pain: initial report. Clin. J. Pain28(2) , 108–112 (2012).
  • Jin L , KolleweK, KrampflK, DenglerR, MohammadiB. Treatment of phantom limb pain with botulinum toxin type A. Pain Med.10(2) , 300–303 (2009).
  • Kapural L , StillmanM, KapuralM, McintyreP, GuirgiusM, MekhailN. Botulinum toxin occipital nerve block for the treatment of severe occipital neuralgia: a case series. Pain Pract.7(4) , 337–340 (2007).
  • Taylor M , SilvaS, CottrellC. Botulinum toxin type-A (BOTOX) in the treatment of occipital neuralgia: a pilot study. Headache48(10) , 1476–1481 (2008).
  • Bakheit AM , ThilmannAF, WardAB et al. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 31(10) , 2402–2406 (2000).
  • Bakheit AM , PittockS, MooreAP et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur. J. Neurol. 8(6) , 559–565 (2001).
  • Rosales RL , KongKH, GohKJ et al. Botulinum toxin injection for hypertonicity of the upper extremity within 12 weeks after stroke. a randomized controlled trial. Neurorehabil. Neural Repair. 26(7) , 812–821 (2012).
  • Kaji R , OsakoY, SuyamaK et al. Botulinum toxin type A in post-stroke upper limb spasticity. Curr. Med. Res. Opin. 26(8) , 1983–1992 (2010).
  • Kanovsky P , SlawekJ, DenesZ et al. Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity. Clin. Neuropharmacol. 32(5) , 259–265 (2009).
  • McCrory P , Turner-StokesL, BaguleyIJ et al. Botulinum toxin A for treatment of upper limb spasticity following stroke: a multi-centre randomized placebo-controlled study of the effects on quality of life and other person-centred outcomes. J. Rehabil. Med. 41(7) , 536–544 (2009).
  • Lam K , LauKK, SoKK et al. Can botulinum toxin decrease carer burden in long term care residents with upper limb spasticity? A randomized controlled study. J. Am. Med. Dir. Assoc. 13(5) , 477–484 (2012).
  • Childers MK , BrashearA, JozefczykP et al. Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. Arch. Phys. Med. Rehabil. 85(7) , 1063–1069 (2004).
  • Richardson D , SheeanG, WerringD et al. Evaluating the role of botulinum toxin in the management of focal hypertonia in adults. J. Neurol. Neurosurg. Psychiatry 69(4) , 499–506 (2000).
  • Smith SJ , EllisE, WhiteS, MooreAP. A double-blind placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury. Clin. Rehab.14(1) , 5–13 (2000).
  • Suputtitada A , SuwanwelaNC. The lowest effective dose of botulinum A toxin in adult patients with upper limb spasticity. Disabil. Rehabil.27(4) , 176–184 (2005).
  • Brashear A , McafeeAL, KuhnER, FyffeJ. Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled trial. Arch. Phys. Med. Rehabil.85(5) , 705–709 (2004).
  • Brashear A , GordonMF, ElovicE et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N. Engl. J. Med. 347(6) , 395–400 (2002).
  • Simpson DM , AlexanderDN, O‘brienCF et al. Botulinum toxin type A in the treatment of upper extremity spasticity. a randomized, double-blind, placebo-controlled trial. Neurology 46(5) , 1306–1310 (1996).
  • Bhakta BB , CozensJA, ChamberlainMA, BamfordJM. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J. Neurol. Neurosurg. Psychiatry69(2) , 217–221 (2000).
  • Marco E , DuarteE, VilaJ et al. Is botulinum toxin type A effective in the treatment of spastic shoulder pain in patients after stroke? A double-blind randomized clinical trial. J. Rehabil. Med. 39(6) , 440–447 (2007).
  • Hesse S , ReiterF, KonradM, JahnkeMT. Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double-blind, placebo-controlled trial. Clin. Rehab.12(5) , 381–388 (1998).
  • Shaw LC , PriceCI, Van Wijck FM et al. Botulinum Toxin for the Upper Limb after Stroke (BoTULS) Trial. effect on impairment, activity limitation, and pain. Stroke42(5) , 1371–1379 (2011).
  • Simpson DM , GraciesJM, YablonSA, BarbanoR, BrashearA, BoNTTZDST. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study. J. Neurol. Neurosurg. Psychiatry80(4) , 380–385 (2009).
  • Lim JY , KohJH, PaikNJ. Intramuscular botulinum toxin-A reduces hemiplegic shoulder pain: a randomized, double-blind, comparative study versus intraarticular triamcinolone acetonide. Stroke39(1) , 126–131 (2008).
  • Kaji R , OsakoY, SuyamaK et al. Botulinum toxin type A in post-stroke lower limb spasticity. a multicenter, double-blind, placebo-controlled trial. J. Neurol. 257(8) , 1330–1337 (2010).
  • Hyman N , BarnesM, BhaktaB et al. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J. Neurol. Neurosurg. Psychiatry 68(6) , 707–712 (2000).
  • Maanum G , JahnsenR, StanghelleJK, SandvikL, KellerA. Effects of botulinum toxin A in ambulant adults with spastic cerebral palsy: a randomized double-blind placebo controlled-trial. J. Rehabil. Med.43(4) , 338–347 (2011).
  • Pittock SJ , MooreAP, HardimanO et al. A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke. Cerebrovasc. Dis. 15(4) , 289–300 (2003).
  • Dunne JW , GraciesJM, HayesM, ZemanB, SingerBJ, Multicentre Study G. A prospective, multicentre, randomized, double-blind, placebo-controlled trial of onabotulinumtoxinA to treat plantarflexor/invertor overactivity after stroke. Clin. Rehab.26(9) , 787–797 (2012).
  • Karadag-Saygi E , Cubukcu-AydoseliK, KablanN, OfluogluD. The role of kinesiotaping combined with botulinum toxin to reduce plantar flexors spasticity after stroke. Top. Stroke Rehabil.17(4) , 318–322 (2010).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.